Very late-onset membranous nephropathy secondary to alemtuzumab in a patient with multiple sclerosis

Introduction Multiple sclerosis (MS) is a chronic multifocal inflammatory demyelinating disease that progresses with neurodegeneration and is associated with a high risk of disability. Objectives We describe a series of patients diagnosed with MS in […]

Introducción Alemtuzumab es un fármaco de alta eficacia aprobado por la Agencia Europea de Medicamentos como tratamiento modificador de la enfermedad en pacientes con esclerosis múltiple remitente recurrente. Objetivo Elaborar un documento de consenso sobre […]

Background Multiple sclerosis (MS) is a chronic immunological, inflammatory, demyelinating, and neurodegenerative disease. Nutrition has been considered a possible factor in the pathogenesis of MS for some years. There is currently no consensus on the […]